Aprea Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Aprea Therapeutics sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 1 currently recruiting 5 completed early-phase tilt top decile by trial count

Aprea Therapeutics: 9 sponsored US clinical trials, 1 recruiting.

Aprea Therapeutics sponsors 9 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 5 completed. 1 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Solid Tumor, with 2 trials.

Top-decile sponsor footprint

Aprea Therapeutics ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 1

Study of APR-1051 in Patients With Advanced Solid Tumors

NCT06260514
ACTIVE NOT RECRUITING Phase 1

Study Of ATRN-119 In Patients With Advanced Solid Tumors

NCT04905914
TERMINATED Phase 1

APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)

NCT04638309
TERMINATED Phase 1

APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)

NCT04419389
COMPLETED Phase 1

Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies

NCT04383938
COMPLETED Phase 1

APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

NCT04214860
COMPLETED Phase 2

APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant

NCT03931291
COMPLETED Phase 3

APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

NCT03745716
COMPLETED Phase 1

p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

NCT02098343

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 1
Phase 3 1

Therapeutic Areas

Advanced Solid Tumor 2
Acute Myeloid Leukemia or Myelodysplastic Syndromes 1
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 1
MDS 1

What is open in the Aprea Therapeutics pipeline

1 recruiting of 9 indexed (11% open); 5 completed (56%).

Phase mix: 1 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Advanced Solid Tumor (2 trials), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Aprea Therapeutics: open-pipeline peers nationwide

Peers matched on 9 registered trials and 11% open enrollment, not the therapeutic-area sidebar.

Aprea Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 01020304050 0%10%20%30%40%50% Total trials Recruiting share Aprea Therapeutics4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyADC Therapeutics S.A.Adrian VellaAIDS Malignancy ConsortiumAmylyx Pharmaceuticals
Aprea Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Aprea Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 11% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Aprea Therapeutics page

9 registered trials is a research-attention snapshot, not an endorsement of Aprea Therapeutics or any single study.

  • 1 of Aprea Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Advanced Solid Tumor is the condition Aprea Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Solid Tumor trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Aprea Therapeutics pipeline card: 9 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.